BioNTech Investor Day Presentation Deck

iNeST I Autogene cevumeran (BNT122) Driving continuous iNeST innovation with data 1 Individual patient samples (blood and tissue) Driven by data Constant improvement as more data are generated and analyzed iNeST is being developed in collaboration with Genentech. NORMAL 2 GGGAAACTTTTTCC TUMOR GGGAAACGTTTTCC Mapping of mutations 3 Neoantigen prediction Selection algorithms Al and ML optimization Continuous platform evolution 4 On-demand tailored RNA manufacturing 5 Individualized immunotherapy NUM mRNA cancer vaccines Just-in-time manufacturing Dedicated mRNA GMP production facilities Targeting delivery of <5 weeks BIONTECH 97

View entire presentation